Evidence map›Paper›PMID 39673128›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Self-amplifying mRNA vaccines protect elderly BALB/c mice against a lethal respiratory syncytial virus infection.

Lulu Zuo, Qixing Liu, Ke Zhang, Lu Zhao, Siyu Lin, You Dai, Yun Sun, Yingwen Li, Pingping Zhang, Huyan Shen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lulu ZuoViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
Qixing LiuViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Nucleic Acid Research, Hongene Biotech, Shanghai 201203, China.
Ke ZhangViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China; Guizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control/Institute of Virology, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China.
Lu ZhaoInstitute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
Siyu LinGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control/Institute of Virology, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China.
You DaiGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control/Institute of Virology, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China.
Yun SunCollege of Life Sciences, Nanjing Normal University, Nanjing 210023, China.
Yingwen LiViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Pingping ZhangGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control/Institute of Virology, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China.
Huyan ShenGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control/Institute of Virology, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China.
Dongmei HeInstitute of Pathogenic Microorganisms, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China; Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangzhou 511430, China.
Shuang MaDepartment of Clinical Laboratory, Huadu Maternal and Child Health Care Hospital, Guangzhou 511430, China.
Xianhua LongGuangzhou DAAN Clinical Laboratory Center, Guangzhou 510665, China.
Yanhua ChenViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China.
Yusi LuoDepartment of Emergency ICU, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China. Electronic address: roseluogy@outlook.com.
Gary WongViral Hemorrhagic Fevers Research Unit, Institut Pasteur of Shanghai (now Shanghai Institute of Immunity and Infection), Chinese Academy of Sciences, Shanghai 201203, China; Virology Laboratory, Institut Pasteur du Laos, Vientiane 01030, Laos. Electronic address: g.wong@pasteur.la.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) represents a significant threat, being a primary cause of critical lower respiratory tract infections and fatalities among infants and the elderly worldwide, and poses a challenge to global public health. This urgent public health challenge necessitates the swift development of safe and effective vaccines capable of eliciting robust immune responses at low doses. Addressing this need, our study investigated five self-amplifying mRNA (sa-mRNA) candidate vaccines that encode the various pre-fusion conformations of the RSV fusion protein. When administered via low-dose intramuscular injection to 8-month-old elderly mice, these vaccines triggered potent humoral reactions and T helper type 1-biased cellular immunity. A prime-boost strategy followed by challenge with a lethal, mouse-adapted RSV strain showed that three of these sa-mRNA candidates achieved greater than 80% survival rates. An immune correlates of protection analysis contrasting immunized survivors with non-survivors suggest that the titers of IgG and neutralizing antibody are associated with vaccine-mediated protection from RSV infection. Our results highlight the usefulness of sa-mRNA vaccines to play a crucial role in forging an effective defense against RSV, addressing a critical need in protecting vulnerable populations against this virus.

Indexed as

mRNA VaccinesRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRNA, MessengerAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalFemaleHumansImmunity, CellularImmunoglobulin GMiceMice, Inbred BALB CRespiratory Syncytial Virus, HumanAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GmRNA VaccinesRespiratory Syncytial Virus VaccinesRNA, MessengerViral Fusion Proteinscorrelates of protectionlethal animal modelrespiratory syncytial virusRSVsa-mRNA vaccineself-amplifying mRNAvaccine

Identifiers

PMID39673128
PMCPMC11852396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.